Evaluation of lung lobectomy and adjuvant treatment for primary pulmonary carcinoma in dogs: 89 cases (2005‐2022)
Journal of Small Animal Practice · 2025
DOI: 10.1111/jsap.13874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Small Animal Practice, 2025. Verfasst von E Treggiari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncopets, Milan, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Dog Diseases, Pneumonectomy, Carcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Objectives
Primary lung cancer is relatively common in dogs. Despite the existing literature on long‐term follow‐up and outcome, further clinical studies focusing on a single histotype are needed, specifically about epithelial tumours since they are the ones most frequently detected. Materials and Methods The medical records of four European institutions were reviewed to identify dogs undergoing lung lobectomy for a primary lung carcinoma between 2005 and 2022.
Results
A total of 89 dogs were included. Median age was 11 years (range 5 to 17 years) and median body weight was 23 kg (range 2.5 to 47 kg). Overall median survival time was 252 days (range 6 to 1558 days) and overall progression‐free interval was 140 days (range 7 to 684 days). The 1‐, 2‐ and 3‐year survival rates were 61%, 47% and 30%, respectively. Presence of clinical signs at presentation, pleural effusion, completeness of surgical margins, histopathological features and use of adjuvant chemotherapy did not influence survival. Patients with maximum tumour diameter ≥ 5 cm had a reduced survival compared to patients with smaller tumours (median survival time 284 days vs. 717 days, 95% CI 8 to 719), and dogs with histologically confirmed lymph node metastasis had a reduced survival compared to patients with no evidence of local metastasis (median survival time 162 days vs. 614 days, 95% CI 39 to 760). None of the other assessed variables influenced progression‐free interval. Clinical Significance Dogs with primary pulmonary carcinoma with no lymph node involvement and with a maximum tumour diameter of < 5 cm may have a better prognosis and prolonged survival. Further studies are needed to elucidate the role of adjuvant chemotherapy in case of clinically aggressive lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Oncopets, Milan, Italy.
- Clinica Veterinaria Malpensa AniCura, Samarate, Italy.
- Ospedale Veterinario I Portoni Rossi AniCura, Zola Predosa, Italy.
- Royal Veterinary College, Queen's Mother Hospital for Animals, Hertfordshire, UK.
ORCID-Profile: E Treggiari, M Rossanese
Zitieren
APA
Treggiari, E., Romanelli, G., Valenti, P., Montinaro, V., & Rossanese, M. (2025). Evaluation of lung lobectomy and adjuvant treatment for primary pulmonary carcinoma in dogs: 89 cases (2005‐2022). Journal of Small Animal Practice. https://doi.org/10.1111/jsap.13874
Vancouver
Treggiari E, Romanelli G, Valenti P, Montinaro V, Rossanese M. Evaluation of lung lobectomy and adjuvant treatment for primary pulmonary carcinoma in dogs: 89 cases (2005‐2022). Journal of Small Animal Practice. 2025. doi:10.1111/jsap.13874
BibTeX
@article{Treggiari2025,
author = {Treggiari, E and Romanelli, G and Valenti, P and Montinaro, V and Rossanese, M},
title = {Evaluation of lung lobectomy and adjuvant treatment for primary pulmonary carcinoma in dogs: 89 cases (2005‐2022)},
journal = {Journal of Small Animal Practice},
year = {2025},
doi = {10.1111/jsap.13874}
}
EUVIMED